One year after his arrest, PixarBio CEO Francis Reynolds was convicted of defrauding investors of $12.7 million.
Baxter International Inc. was named in a complaint for improperly marketing opioid drugs and revealed an internal probe into the medical supplier’s accounting, sending the company’s shares down.
Catalyst Pharmaceuticals Inc., under fire for a high price tag on a rare disease drug, sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival medicine.
Vaunted immunotherapy pioneers from the Dana-Farber Cancer Institute won a key court case that could be worth billions of dollars.
British drugmaker Vectura Group Plc won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and was awarded $89.7 million in damages for the period from August 2016 through December 2018.
Generic competitors to British drugmaker Indivior Plc’s blockbuster opioid addiction treatment are on course to launch after the firm’s attempt to stay a U.S. District court judgement was rejected.
Ironwood Pharmaceuticals Inc. and Allergan plc announced that the companies reached an agreement with Mylan Pharmaceuticals Inc. resolving patent litigations brought in response to Mylan’s abbreviated new drug applications seeking approval to market generic versions of Linzess (linaclotide) before the expiration of the companies’ applicable patents.
Boston Scientific exercised the company’s option to buy the remaining shares of Santa Rosa, Calif.-based Millipede for $325 million.